ANDA 90780, held by Everest Lifesciences. Duloxetine Hydrochloride.
As of Nov 16, 2026, ANDA 90780 (Duloxetine Hydrochloride), held by Everest Lifesciences, was first approved by FDA on Oct 28, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2015 | Original application | Approved |
| Duloxetine HydrochlorideEQ 20MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
| Duloxetine HydrochlorideEQ 30MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
| Duloxetine HydrochlorideEQ 60MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters